Martin is Principal based in the Boston office. Martin’s primary area of interest is in biotechnology investments in a range of therapeutic areas including oncology, cardiovascular, renal and metabolic diseases. Martin joined F-Prime’s London office in 2019, where he has worked on several biotechnology company creation efforts and investments in Europe, including ARTBIO, CHARM Therapeutics and Tenpoint Therapeutics.

Prior to joining F-Prime, he was a Wellcome Trust Sir Henry Wellcome Postdoctoral Fellow at the MRC Laboratory of Molecular Biology in Cambridge, where he researched molecular mechanisms of DNA replication. Martin completed his PhD at the Cancer Research UK London Research Institute, prior to its incorporation into the Francis Crick Institute, investigating DNA repair by homologous recombination. His research has been published in several original articles in journals such as Cell, Nature and Molecular Cell. Martin also holds BA and MSci degrees in Biochemistry from the University of Cambridge.